Vishal Manchanda

Vishal Manchanda is an analyst at Systematix Institutional Equities, where he focuses on the pharmaceutical sector. He has analyzed the pricing dynamics of weight-loss medications, predicting significant price corrections for Wegovy as generic versions enter the Indian market, which could greatly affect its accessibility for consumers.